A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

被引:14
|
作者
Lombard, Louise [1 ]
Nutr, M. [1 ]
Ye, Wenyu [1 ]
Nichols, Russell [1 ]
Jackson, James [2 ]
Cotton, Sarah [2 ]
Joshi, Shivang [3 ,4 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Adelphi Real World, Adelphi Mill, Bollington, England
[3] DENT Neurol Inst, Amherst, NY USA
[4] Univ Buffalo, Sch Pharm, Buffalo, NY USA
来源
HEADACHE | 2020年 / 60卷 / 07期
关键词
migraine; responder; insufficient responder; real-world; acute treatment; UNITED-STATES; PREVALENCE; HEADACHE; PREVENTION; NONRESPONDERS; DISABILITY; TRIALS; ADULTS;
D O I
10.1111/head.13835
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective The objective of this study was to examine if patients with migraine who responded sufficiently to acute treatment were significantly different from those who did not in terms of patient characteristics, treatment patterns, and patient level of impairment, and to identify characteristics associated with insufficient response. Background Migraine is highly prevalent and impacts functional ability substantially. Current treatment approaches are not sufficiently meeting the needs of patients, and inadequate response to acute treatment is reported by at least 56% of patients with migraine in the United States. Methods Data were obtained from the 2014 Adelphi Migraine Disease-Specific Program, a cross-sectional survey. Using logistic regression, we assessed the association between patient factors and insufficient response. Responders were defined as patients with migraine who achieved pain freedom within 2 hours of acute treatment in >= 4 of 5 attacks, while insufficient responders achieved it in <= 3 of 5 attacks. Results Of 583 patients included, insufficient responders to acute treatment constituted 34.3% (200/583) of the study population. A statistically significantly larger proportion of insufficient responders vs responders had >= 4 migraine headache days/month (46.3% [88/190] vs 31% [114/368]), had ever been prescribed >= 3 unique preventive treatment regimens (11.7% [21/179] vs 6.3% [22/347]), and had chronic migraine, medication-overuse headaches, and comorbid depression (all P values <=.05). Patient level of impairment was statistically significantly greater among insufficient responders vs responders. Factors associated with insufficient response after adjusting for covariates included Migraine Disability Assessment total score (odds ratio [OR] = 1.04, 95% CI [1.02, 1.05]), time of administration of acute treatment (OR = 1.83, 95% CI [1.15, 2.92]), depression (OR = 1.98, 95% CI [1.21, 3.23]), sensitivity to light not listed as current most troublesome symptom (OR = 2.30, 95% CI [1.21, 4.37]), and change in the average headache days per month before being prescribed an acute treatment vs now (OR = 1.75, 95% CI [1.05, 2.90]). Conclusions Clinical characteristics, treatment patterns, and health-related quality of life measures are statistically significantly different between insufficient responders and responders to acute treatment in patients with migraine.
引用
收藏
页码:1325 / 1339
页数:15
相关论文
共 50 条
  • [31] Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
    Kaname Ueda
    Wenyu Ye
    Louise Lombard
    Atsushi Kuga
    Yongin Kim
    Sarah Cotton
    James Jackson
    Tamas Treuer
    The Journal of Headache and Pain, 2019, 20
  • [32] Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension
    Ogbomo, Adesuwa
    Tsang, Yuen
    Kariburyo, Furaha
    Tsai, Wan-Lun
    Panjabi, Sumeet
    PULMONARY THERAPY, 2021, 7 (02) : 575 - 590
  • [33] Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data
    Meyers, Juliana L.
    Davis, Keith L.
    Lenz, Robert A.
    Sakai, Fumihiko
    Xue, Fei
    CEPHALALGIA, 2019, 39 (12) : 1518 - 1534
  • [34] Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis
    Juanzhi Fang
    Stephanie Korrer
    Jonathan C. Johnson
    Mark A. Cheadle
    Roshani Shah
    Matias L. Ferraris
    Cristina Lopez-Lopez
    Advances in Therapy, 2021, 38 : 2921 - 2934
  • [35] Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis
    Fang, Juanzhi
    Korrer, Stephanie
    Johnson, Jonathan C.
    Cheadle, Mark A.
    Shah, Roshani
    Ferraris, Matias L.
    Lopez, Cristina
    ADVANCES IN THERAPY, 2021, 38 (06) : 2921 - 2934
  • [36] Acute treatment of migraine: quantifying the unmet need through real-world data in Italy
    Sacco, Simona
    Di Ciaccio, Sonia
    Di Virgilio, Roberto
    Pegoraro, Valeria
    Ornello, Raffaele
    NEUROLOGICAL SCIENCES, 2024, 45 (09) : 4427 - 4435
  • [37] Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry
    Bidin, Mohamed Badrulnizam Long
    Khan, Abdul Mueed
    Tan, Florence Hui Sieng
    Aziz, Nor Azizah
    Ali, Norhaliza Mohd
    Kamaruddin, Nor Azmi
    Vethakkan, Shireene Ratna
    Sethi, Balraj
    Hussein, Zanariah
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2023, 38 (01): : 75 - 80
  • [38] Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage
    Wilke, Thomas
    Picker, Nils
    Mueller, Sabrina
    Geier, Silke
    Foersch, Johannes
    Aberle, Jens
    Martin, Stephan
    Riedl, Matthias
    Gabler, Maximilian
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 1225 - 1237
  • [39] Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
    Richard B. Lipton
    Rashmi B. Halker Singh
    Dennis A. Revicki
    Sihui Zhao
    Anand R. Shewale
    Jordan E. Lateiner
    David W. Dodick
    The Journal of Headache and Pain, 2022, 23
  • [40] Real-world treatment patterns of benralizumab therapy for patients with severe asthma
    Gendron, Alain
    Sriskandarajah, Niroshan
    Johnston, Karissa
    Osenenko, Kathy M.
    Noorduyn, Stephen G.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56